Drug Trial Radar · NCT06363383
A Phase 1 Study to Evaluate the Safety of an Oral Biologic in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
May 9, 2024
Primary completion
Jul 4, 2025
Study completion Jul 4, 2025
Sponsor
- Lead sponsor
- Mage BiologicsIndustry
- Sponsor type
- Industry
- Collaborators
- Alimentiv Inc.
- First posted
- Apr 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if the oral biologic MB-001 is safe in healthy volunteers. The main questions it aims to answer are: Is the drug safe when administered orally at increasing doses? Researchers will compare the drug with placebo to see if there are more side effects in those receiving the drug. Participants will receive a single or five daily doses of the drug or placebo and will be asked to stay in the clinic for five days following the last dose.
Conditions
- Ulcerative Colitis
Interventions
MB-001Biological
Oral, delayed release formulation of a biologic drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AEs)Time frame: up to day 33 post dosing
- Clinically significant changes from baseline in vital signsTime frame: up to day 33 post dosing
- Clinically significant changes from baseline in physical examination findingsTime frame: up to day 33 post dosing
- Clinically significant changes from baseline in clinical laboratory assessmentsTime frame: up to day 33 post dosing
- Clinically significant changes from baseline in ECG parametersTime frame: up to day 33 post dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.